These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24384233)

  • 41. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness.
    Grcevic D; Jajic Z; Kovacic N; Lukic IK; Velagic V; Grubisic F; Ivcevic S; Marusic A
    J Rheumatol; 2010 Feb; 37(2):246-56. PubMed ID: 20008919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.
    Kayagaki N; Yamaguchi N; Nakayama M; Takeda K; Akiba H; Tsutsui H; Okamura H; Nakanishi K; Okumura K; Yagita H
    J Immunol; 1999 Aug; 163(4):1906-13. PubMed ID: 10438925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway.
    Liu B; Fan Z
    Oncogene; 2001 Jun; 20(28):3726-34. PubMed ID: 11439335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
    Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
    Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
    Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
    Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.
    Hemmerle T; Probst P; Giovannoni L; Green AJ; Meyer T; Neri D
    Br J Cancer; 2013 Sep; 109(5):1206-13. PubMed ID: 23887603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling.
    Obungu VH; Gelfanova V; Rathnachalam R; Bailey A; Sloan-Lancaster J; Huang L
    Biochemistry; 2009 Aug; 48(30):7251-60. PubMed ID: 19588926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
    Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
    Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins.
    Sharifi J; Khawli LA; Hu P; Li J; Epstein AL
    Hybrid Hybridomics; 2002 Dec; 21(6):421-32. PubMed ID: 12573106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human.
    Bossen C; Ingold K; Tardivel A; Bodmer JL; Gaide O; Hertig S; Ambrose C; Tschopp J; Schneider P
    J Biol Chem; 2006 May; 281(20):13964-71. PubMed ID: 16547002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.
    Ślebioda TJ; Kmieć Z
    Mediators Inflamm; 2014; 2014():325129. PubMed ID: 25045210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.
    Bootz F; Schmid AS; Neri D
    Inflamm Bowel Dis; 2015 Aug; 21(8):1908-17. PubMed ID: 25993691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling.
    Zhu M; Fu YX
    Immunol Rev; 2011 Nov; 244(1):75-84. PubMed ID: 22017432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor necrosis factor superfamily in innate immunity and inflammation.
    Šedý J; Bekiaris V; Ware CF
    Cold Spring Harb Perspect Biol; 2014 Dec; 7(4):a016279. PubMed ID: 25524549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor necrosis factor: renaissance as a cancer therapeutic?
    Daniel D; Wilson NS
    Curr Cancer Drug Targets; 2008 Mar; 8(2):124-31. PubMed ID: 18336195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12.
    Bootz F; Venetz D; Ziffels B; Neri D
    Protein Eng Des Sel; 2016 Oct; 29(10):445-455. PubMed ID: 27515704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.
    Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D
    J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An engineered 4-1BBL fusion protein with "activity on demand".
    Mock J; Stringhini M; Villa A; Weller M; Weiss T; Neri D
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31780-31788. PubMed ID: 33239441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
    De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
    Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.